SCHEMBL940763

SCHEMBL940763

COC([O])(Cc1ccccc1)OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.46
TAAR1 Q96RJ0 1/20 0.46
LMNA P02545 1/20 0.43
CYP2D6 P10635 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
HIF1A Q16665 1/20 0.42
FDPS P14324 1/20 0.41
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP1A2 P05177 1/20 0.40
EPHX2 P34913 1/20 0.39
LTA4H P09960 1/20 0.39
TP53 P04637 1/20 0.39
TRPA1 O75762 1/20 0.38
PTPN2 P17706 1/20 0.38
PTPN1 P18031 1/20 0.38
PTPRA P18433 1/20 0.38
PTPRB P23467 1/20 0.38
ALDH1A1 P00352 3/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1357604 0.80 SLC6A2 (0.50) SLC6A2TAAR1LMNACYP2D6SMN1; SMN2
SCHEMBL5682273 0.78 SLC6A2 (0.43) SLC6A2TAAR1LMNACYP2D6SMN1; SMN2
SCHEMBL11211433 0.77 SLC6A2 (0.46) SLC6A2TAAR1LMNACYP2D6SMN1; SMN2
SCHEMBL4964541 0.76 SLC6A2 (0.50) SLC6A2TAAR1LMNACYP2D6SMN1; SMN2
SCHEMBL6909686 0.76 SLC6A2 (0.50) SLC6A2TAAR1LMNACYP2D6SMN1; SMN2
SCHEMBL5088767 0.76 SLC6A2 (0.50) SLC6A2TAAR1LMNACYP2D6SMN1; SMN2
Methane SCHEMBL27048839 0.74 TAAR1 (0.48) SLC6A2TAAR1LMNACYP2D6SMN1; SMN2
SCHEMBL10462120 0.74 SLC6A2 (0.54) SLC6A2TAAR1LMNACYP2D6SMN1; SMN2
SCHEMBL872871 0.74 SLC6A2 (0.54) SLC6A2TAAR1LMNACYP2D6SMN1; SMN2
SCHEMBL94458 0.73 SLC6A2 (0.58) SLC6A2TAAR1LMNACYP2D6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9263767-B2 Electrolyte solution for electrochemical devices WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2016-02-16 US disclosed
US-20140162143-A1 ELECTROLYTE SOLUTION FOR ELECTROCHEMICAL DEVICES WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2014-06-12 US disclosed
EP-2738862-A1 ELECTROLYTE SOLUTION FOR ELECTROCHEMICAL DEVICES Wako Pure Chemical Industries, Ltd. (JP) 2014-06-04 EP disclosed
US-8163938-B2 Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2012-04-24 US disclosed
EP-1666459-B1 Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP (CA) 2011-10-19 EP disclosed
EP-2298735-A1 Aminocyclohexyl ether compounds and uses thereof Cardiome Pharma Corp. (CA) 2011-03-23 EP disclosed
US-20110004006-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2011-01-06 US disclosed
US-7767830-B2 Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2010-08-03 US disclosed
US-7345087-B2 Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2008-03-18 US disclosed
US-20070254945-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2007-11-01 US disclosed
US-20070197632-A1 Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP (CA) 2007-08-23 US disclosed
US-20070099983-A1 Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2007-05-03 US disclosed
US-20060247300-A1 Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP (CA) 2006-11-02 US disclosed
EP-1666459-A2 Aminocyclohexyl ether compounds and uses thereof Cardiome Pharma Corp. (CA) 2006-06-07 EP disclosed
EP-1560812-B1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP (CA) 2006-05-10 EP disclosed
EP-1560812-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF Cardiome Pharma Corp. (CA) 2005-08-10 EP disclosed
WO-2004099137-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110004006-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF KCNH2, KCNC1, KCNH3 SLC6A2 1012/4885TAAR1 820/4885LMNA 392/4885
US-20070254945-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF KCNH2, KCNC1, KCNH3 SLC6A2 1012/4885TAAR1 820/4885LMNA 392/4885
US-20070197632-A1 Aminocyclohexyl ether compounds and uses thereof KCNH2, KCNC1, KCNH3 SLC6A2 1012/4885TAAR1 820/4885LMNA 392/4885
US-20070099983-A1 Aminocyclohexyl ether compounds and uses thereof KCNH2, KCNC1, KCNH3 SLC6A2 1012/4885TAAR1 820/4885LMNA 392/4885
US-20060247300-A1 Aminocyclohexyl ether compounds and uses thereof KCNH2, KCNC1, KCNH3 SLC6A2 1012/4885TAAR1 820/4885LMNA 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.